<!DOCTYPE html>
<html lang="ja">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Pharma Daily Brief | PiercePharma 朝刊</title>
  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  <link href="https://fonts.googleapis.com/css2?family=Noto+Sans+JP:wght@400;500;600;700&family=IBM+Plex+Sans:wght@400;500;600&display=swap" rel="stylesheet">
  <style>
    :root {
      --bg-main: #0f1419;
      --bg-card: #1a2332;
      --bg-card-hover: #232f42;
      --text-primary: #e8edf4;
      --text-secondary: #94a3b8;
      --text-muted: #64748b;
      --accent-pipeline: #38bdf8;
      --accent-regulatory: #fb923c;
      --accent-deals: #4ade80;
      --accent-earnings: #a78bfa;
      --border: #2d3a4f;
      --link: #7dd3fc;
      --link-hover: #bae6fd;
    }
    * { box-sizing: border-box; margin: 0; padding: 0; }
    body { font-family: 'IBM Plex Sans', 'Noto Sans JP', sans-serif; background: var(--bg-main); color: var(--text-primary); line-height: 1.6; min-height: 100vh; padding: 24px 16px; }
    .container { max-width: 720px; margin: 0 auto; }
    .header { margin-bottom: 32px; padding-bottom: 20px; border-bottom: 1px solid var(--border); }
    .header h1 { font-size: 1.5rem; font-weight: 700; letter-spacing: -0.02em; }
    .header .date { font-size: 0.875rem; color: var(--text-muted); margin-top: 4px; font-weight: 500; }
    .header .subtitle { font-size: 0.8125rem; color: var(--text-secondary); margin-top: 8px; }
    .header .scope { font-size: 0.75rem; color: var(--text-muted); margin-top: 12px; padding: 10px 12px; background: var(--bg-card); border-radius: 6px; border: 1px solid var(--border); line-height: 1.5; }
    .header .scope strong { color: var(--text-secondary); }
    .category-section { margin-bottom: 28px; }
    .category-header { display: flex; align-items: center; gap: 8px; margin-bottom: 12px; font-size: 0.8125rem; font-weight: 600; text-transform: uppercase; letter-spacing: 0.05em; }
    .category-header .badge { width: 8px; height: 8px; border-radius: 50%; }
    .category-pipeline .badge { background: var(--accent-pipeline); } .category-pipeline .category-header { color: var(--accent-pipeline); }
    .category-regulatory .badge { background: var(--accent-regulatory); } .category-regulatory .category-header { color: var(--accent-regulatory); }
    .category-deals .badge { background: var(--accent-deals); } .category-deals .category-header { color: var(--accent-deals); }
    .category-earnings .badge { background: var(--accent-earnings); } .category-earnings .category-header { color: var(--accent-earnings); }
    .article-card { background: var(--bg-card); border: 1px solid var(--border); border-left: 3px solid; border-radius: 8px; padding: 16px; margin-bottom: 12px; transition: background 0.2s; }
    .article-card:hover { background: var(--bg-card-hover); }
    .article-card.pipeline { border-left-color: var(--accent-pipeline); }
    .article-card.regulatory { border-left-color: var(--accent-regulatory); }
    .article-card.deals { border-left-color: var(--accent-deals); }
    .article-card.earnings { border-left-color: var(--accent-earnings); }
    .article-card .title { font-size: 1rem; font-weight: 600; margin-bottom: 8px; line-height: 1.4; }
    .article-card .title a { color: var(--text-primary); text-decoration: none; transition: color 0.2s; }
    .article-card .title a:hover { color: var(--link-hover); }
    .article-card .summary { font-size: 0.875rem; color: var(--text-secondary); margin-bottom: 10px; line-height: 1.5; }
    .article-card .meta { display: flex; flex-wrap: wrap; gap: 12px; font-size: 0.75rem; color: var(--text-muted); }
    .article-card .meta span { display: inline-flex; align-items: center; gap: 4px; }
    .article-card .link-wrap { margin-top: 10px; }
    .article-card .link-wrap a { font-size: 0.8125rem; color: var(--link); text-decoration: none; transition: color 0.2s; }
    .article-card .link-wrap a:hover { color: var(--link-hover); text-decoration: underline; }
    .article-card .link-wrap a::after { content: '→'; }
    .importance { display: inline-flex; gap: 2px; }
    .importance .star { color: var(--accent-regulatory); font-size: 0.7rem; }
    .importance .star.empty { color: var(--text-muted); opacity: 0.5; }
    .article-card .meta .region { font-size: 0.7rem; padding: 2px 6px; border-radius: 4px; font-weight: 500; }
    .region-us { background: rgba(56,189,248,0.2); color: var(--accent-pipeline); }
    .region-europe { background: rgba(251,146,60,0.2); color: var(--accent-regulatory); }
    .region-china { background: rgba(74,222,128,0.2); color: var(--accent-deals); }
    @media (max-width: 480px) { body { padding: 16px 12px; } .header h1 { font-size: 1.25rem; } .article-card { padding: 14px; } }
  </style>
</head>
<body>
  <div class="container">
    <header class="header">
      <h1>Pharma Daily Brief</h1>
      <div class="date">2026年02月26日（木）</div>
      <div class="subtitle">パイプライン・規制・M&A・決算｜医薬・バイオ業界の重要ニュース（毎朝更新）</div>
      <div class="scope">
        <strong>対象地域：</strong>約9割は米国。欧州はノボノルディスク、ブリストルマイヤーズスクイーブ、サノフィ、ロッシュ、バイエルなど大手の重要ニュースを追加。中国は個別企業より<strong>医薬品規制当局の動向</strong>（変化が大きい場合）を掲載。
      </div>
    </header>


    <section class="category-section category-pipeline">
      <h2 class="category-header">
        <span class="badge"></span>
        Pipeline
      </h2>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/biotech/talking-brick-wall-senate-hearing-takes-aim-fdas-rare-disease-review-process" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/biotech/talking-brick-wall-senate-hearing-takes-aim-fdas-rare-disease-review-process&quot; hreflang=&quot;en&quot;&gt;&#x27;Like talking to a brick wall&#x27;: Senate hearing takes aim at FDA&#x27;s rare disease review process&lt;/a&gt;</a></h3>
        <p class="summary">A panel of physicians, biotech leaders and patient advocates took aim at the FDA during a Senate hearing on how the agency’s bureaucracy affects innovation.</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/biotech/talking-brick-wall-senate-hearing-takes-aim-fdas-rare-disease-review-process" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/pharma/boehringers-hernexeos-secures-speedy-first-line-expansion-fdas-2nd-national-priority-nod" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/pharma/boehringers-hernexeos-secures-speedy-first-line-expansion-fdas-2nd-national-priority-nod&quot; hreflang=&quot;en&quot;&gt;Boehringer&#x27;s Hernexeos secures speedy first-line expansion in FDA&#x27;s 2nd national priority nod &lt;/a&gt;</a></h3>
        <p class="summary">Less than six months after debuting as the first drug that can target a rare tumor type in patients with non-small cell lung cancer, Boehringer Ingelheim’s Hernexeos has quickly widened its reach into…</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/pharma/boehringers-hernexeos-secures-speedy-first-line-expansion-fdas-2nd-national-priority-nod" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/pharma/after-delay-kennedys-cdc-vaccine-panel-sets-new-date-meeting-over-long-covid-and-mrna-shot" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/pharma/after-delay-kennedys-cdc-vaccine-panel-sets-new-date-meeting-over-long-covid-and-mrna-shot&quot; hreflang=&quot;en&quot;&gt;After delay, CDC vaccine panel sets new dates to discuss long COVID and mRNA shot safety&lt;/a&gt;</a></h3>
        <p class="summary">Following an unexpected delay of the CDC vaccine panel&#x27;s February meeting, the Advisory Committee on Immunization Practices (ACIP) has selected dates next month to convene and discuss, among other mat…</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/pharma/after-delay-kennedys-cdc-vaccine-panel-sets-new-date-meeting-over-long-covid-and-mrna-shot" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/pharma/gsks-viiv-confirms-staying-power-long-acting-hiv-treatment-cabenuva-adolescents" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/pharma/gsks-viiv-confirms-staying-power-long-acting-hiv-treatment-cabenuva-adolescents&quot; hreflang=&quot;en&quot;&gt;GSK&#x27;s ViiV confirms staying power of long-acting HIV treatment Cabenuva in adolescents &lt;/a&gt;</a></h3>
        <p class="summary">GSK&#x27;s every-two-month injection kept adolescents with HIV virologically suppressed at 96 weeks, GSK&#x27;s ViiV presented at the recent Conference on Retroviruses and Opportunistic Infections.</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/pharma/gsks-viiv-confirms-staying-power-long-acting-hiv-treatment-cabenuva-adolescents" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/marketing/eisai-points-way-kidney-cancer-support-kompass-digital-hub" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/marketing/eisai-points-way-kidney-cancer-support-kompass-digital-hub&quot; hreflang=&quot;en&quot;&gt;Eisai points the way to kidney cancer support with Kompass digital hub&lt;/a&gt;</a></h3>
        <p class="summary">With a new online resource, Eisai is offering patients and caregivers some direction to help navigate a kidney cancer diagnosis.</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/marketing/eisai-points-way-kidney-cancer-support-kompass-digital-hub" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/pharma/sarepta-ceo-doug-ingram-retire-after-decade-duchenne-breakthroughs-and-controversies" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/pharma/sarepta-ceo-doug-ingram-retire-after-decade-duchenne-breakthroughs-and-controversies&quot; hreflang=&quot;en&quot;&gt;Sarepta CEO Doug Ingram to retire after a decade of Duchenne breakthroughs and controversies&lt;/a&gt;</a></h3>
        <p class="summary">Sarepta Therapeutics CEO Doug Ingram announced Wednesday that he will retire by the end of 2026, citing a “shocking and ironic twist of fate” involving the health of his family.</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/pharma/sarepta-ceo-doug-ingram-retire-after-decade-duchenne-breakthroughs-and-controversies" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/pharma/omg-argenx-scores-again-vyvgart-ocular-myasthenia-gravis" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/pharma/omg-argenx-scores-again-vyvgart-ocular-myasthenia-gravis&quot; hreflang=&quot;en&quot;&gt;OMG—argenx scores again with Vyvgart in ocular myasthenia gravis&lt;/a&gt;</a></h3>
        <p class="summary">Already on a roll with its first-in-class FcRn blocker Vyvgart, argenx has reported successful trial results that could pave the way for the fast-rising blockbuster to reach a new indication—ocular my…</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/pharma/omg-argenx-scores-again-vyvgart-ocular-myasthenia-gravis" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/biotech/protagonist-plans-pocket-400m-takeda-rather-split-us-rusfertide-profits" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/biotech/protagonist-plans-pocket-400m-takeda-rather-split-us-rusfertide-profits&quot; hreflang=&quot;en&quot;&gt;Protagonist plans to pocket $400M from Takeda rather than split US rusfertide profits&lt;/a&gt;</a></h3>
        <p class="summary">While the FDA mulls whether to approve Protagonist Therapeutics’ hematology asset, the biopharma is thinking it will pocket $400 million rather than split profits with Takeda.</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/biotech/protagonist-plans-pocket-400m-takeda-rather-split-us-rusfertide-profits" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/manufacturing/viatris-cut-10-workforce-3-year-overhaul-discloses-fire-india-plant" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/manufacturing/viatris-cut-10-workforce-3-year-overhaul-discloses-fire-india-plant&quot; hreflang=&quot;en&quot;&gt;Viatris to cut 10% of workforce in 3-year overhaul, discloses fire at India plant&lt;/a&gt;</a></h3>
        <p class="summary">Viatris&#x27; three-year reorganization will affect staffers in a range of functions including the company&#x27;s commercial teams, R&amp;D, medical affairs and manufacturing. Besides the layoffs, the drugmaker als…</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/manufacturing/viatris-cut-10-workforce-3-year-overhaul-discloses-fire-india-plant" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/pharma/bridgebios-launch-attruby-accelerates-ceo-says-company-will-rely-its-differentiation" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/pharma/bridgebios-launch-attruby-accelerates-ceo-says-company-will-rely-its-differentiation&quot; hreflang=&quot;en&quot;&gt;As BridgeBio&#x27;s Attruby launch accelerates, CEO shrugs off recent EU pricing pressure fears&lt;/a&gt;</a></h3>
        <p class="summary">When BridgeBio presented its quarterly report on Tuesday, it laid out expectations on the potential threat of generic pricing pressure on Attruby and provided more evidence of the drug&#x27;s strong launch…</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/pharma/bridgebios-launch-attruby-accelerates-ceo-says-company-will-rely-its-differentiation" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>
    </section>

    <footer style="margin-top: 40px; padding-top: 20px; border-top: 1px solid var(--border); font-size: 0.75rem; color: var(--text-muted);">
      Pharma Daily Brief — PiercePharma 朝刊 | 米国中心・欧州大手・中国規制を含む医薬・バイオ業界の重要ニュース
    </footer>
  </div>
</body>
</html>